United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 26, 2009
GeoPharma, Inc.
(Exact name of registrant as specified in its charter)
FL | |
001-16185 | |
59-2600232 |
(State or other jurisdiction
of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| |
6950 Bryan Dairy Road, Largo, FL | |
33777 | |
| | (Address of principal executive offices) | | (Zip Code) | |
Registrant's telephone number, including area code: (727) 544-8866
________________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: (see General Instruction A.2. below)
|
| | [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
On January 26, 2009, GeoPharma, Inc. (the "Company") entered into an agreement with Trident Biotech, Inc. ("Trident"). Under the terms of the agreement, Trident will purchase a majority stake in the Company's Ovarian Cancer business for a total of $2.5 million in cash and notes. The Company will maintain a forty percent ownership in the business.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits. The following documents are filed as exhibits to this report:
99.1 Press release issued January 26, 2009.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | GeoPharma, Inc.
|
| Date: January 27, 2009 | | /s/ MIHIR K. TANEJA
Mihir K. Taneja
Chief Executive Officer
/s/ CAROL DORE-FALCONE
Carol Dore-Falcone
Senior Vice President and Chief Financial Officer |
| | Exhibit Index |
| | 99.1 | Press release dated January 26, 2009 |
